Sun Pharma Advanced Research Company Ltd

{"description":"Sun Pharma shares rose nearly 1% following a 16% increase in net profit for Q3 ended December 31, 2025, reaching Rs 3,369 crore. Total revenue also grew to Rs 15,520 crore. An interim dividend of Rs 11 per share was approved by the board.","url":"https://money.rediff.com/news/market/sun-pharma-shares-rise-after-earnings-report/41185520260201","sentiment":"Positive","domain":"Rediff Money"}

{"description":"On February 1, 2026, Sun Pharma shares rose nearly 4% after the company reported a 16% increase in consolidated net profit for Q3 ending December 31, 2025, amounting to ₹3,369 crore. The firm also announced an interim dividend of ₹11 per share.","url":"https://www.cnbctv18.com/market/stocks/sun-pharma-shares-rise-nearly-4-pc-after-earnings-announcement-ws-l-19838425.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Sun Pharma has made a non-binding offer to acquire US-based Organon, marking its largest global acquisition attempt. The company has secured $10-14 billion in financing from global banks. If successful, this would be the biggest deal by an Indian pharma firm, enhancing Sun's innovation portfolio.","url":"https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-places-non-binding-offer-for-us-based-organon-in-its-boldest-global-bet-ever/articleshow/126714515.cms","sentiment":"Positive","domain":"Indiatimes"}

{"description":"Motilal Oswal maintains a 'Buy' rating on Sun Pharma, expecting a 14% earnings CAGR from FY25-27E, driven by a 17% sales CAGR in specialty and 12% in DF/EM markets. Anticipated 160 basis points margin expansion indicates strong growth potential.","url":"https://www.ndtvprofit.com/research-reports/sun-pharma-is-well-poised-to-sustain-growth-in-focus-segments-says-motilal-oswal-maintaining-buy","sentiment":"Positive","domain":"NDTV Profit"}

{"description":"Sun Pharma's Q1 net profit fell 19.6% YoY to Rs 2,278.6 crore, despite a 9.5% increase in revenue from operations. The decline in profit contrasts with the revenue growth, indicating potential challenges ahead.","url":"https://www.goodreturns.in/news/sun-pharma-q1-fy26-results-net-profit-declines-19-6-yoy-to-2-278-6-crore-despite-9-5-revenue-gro-1446441.html","sentiment":"Negative","domain":"Goodreturns"}

{"description":"Sun Pharma reported a 20% decline in net profit for Q1, totaling Rs 2,278.6 crore, down from Rs 2,835.6 crore in the same quarter last year.","url":"https://www.msn.com/en-in/money/news/sun-pharma-q1-results-net-profit-falls-20-to-rs-2278-crore/ar-AA1JE32E?ocid=BingNewsVerp","sentiment":"Negative","domain":"Zee Business on MSN"}

{"description":"Stocks to watch on July 25 include Sun Pharma, eClerx, IEX, Anant Raj, REC, Aether Industries, L&T, Enviro Infra, GR Infraprojects, and Adani Enterprises, highlighting potential market movements.","url":"https://www.moneycontrol.com/news/business/markets/stocks-to-watch-today-sun-pharma-eclerx-iex-anant-raj-rec-aether-industries-l-t-enviro-infra-gr-infraprojects-adani-enterprises-in-focus-on-25-july-13323266.html","sentiment":"Neutral","domain":"Moneycontrol"}

{"description":"Sun Pharma has launched Leqselvi in the US for alopecia areata following a patent settlement with Incyte Corp, involving an upfront fee and royalties until patent expiry.","url":"https://www.business-standard.com/companies/news/sun-pharma-launches-leqselvi-us-patent-settlement-incyte-125071401218_1.html","sentiment":"Positive","domain":"Business Standard"}